COMPANY NEWS
Essex Bio-Technology appoints Dr. Xue Qi as Chief Scientific Officer for its R&D Centre in USA
2018.04.10
Download
Hong Kong, 9 April 2018
ESSEX BIO-TECHNOLOGY LIMITED (“EssexBio” or the “Group”－Stock code: 1061) is pleased to announce its appointment of Dr. Xue Qi (MD. PhD.) as Chief Scientific Officer of EssexBio and Vice President (Science of Technology) of Essex Bio-Investment Limited. Dr. Xue Qi will lead the R&D Centre in USA, which is being set-up, for R&D projects, primarily in oncology, ophthalmology & dermatology.
Dr. Xue is a well-known global medical science expert in anticancer drug discovery and development. He is highly experienced in tumor microenvironment, immune-oncology and angiogenesis assessment. In June 2014, Dr. Xue obtained his Clinical Research Scholar Certificate from Harvard Medical School in the USA. Dr. Xue graduated from Gunma University in Japan with a PhD degree in Pathology in 2001.
Prior to joining the Group, Dr. Xue has worked for Eli Lilly as one of the key members in its R&D team. He also served as a postdoctoral fellow in Harvard Medical School for nearly seven years since 2002.
The Board of Directors of EssexBio is confident that the addition of Dr. Xue Qi as its CSO will strengthen the Group’s ability in drug discovery and broaden the capability of translational and therapeutics research in its current R&D centre in the PRC.
ESSEX BIO-TECHNOLOGY LIMITED (“EssexBio” or the “Group”－Stock code: 1061) is pleased to announce its appointment of Dr. Xue Qi (MD. PhD.) as Chief Scientific Officer of EssexBio and Vice President (Science of Technology) of Essex Bio-Investment Limited. Dr. Xue Qi will lead the R&D Centre in USA, which is being set-up, for R&D projects, primarily in oncology, ophthalmology & dermatology.
Dr. Xue is a well-known global medical science expert in anticancer drug discovery and development. He is highly experienced in tumor microenvironment, immune-oncology and angiogenesis assessment. In June 2014, Dr. Xue obtained his Clinical Research Scholar Certificate from Harvard Medical School in the USA. Dr. Xue graduated from Gunma University in Japan with a PhD degree in Pathology in 2001.
Prior to joining the Group, Dr. Xue has worked for Eli Lilly as one of the key members in its R&D team. He also served as a postdoctoral fellow in Harvard Medical School for nearly seven years since 2002.
The Board of Directors of EssexBio is confident that the addition of Dr. Xue Qi as its CSO will strengthen the Group’s ability in drug discovery and broaden the capability of translational and therapeutics research in its current R&D centre in the PRC.
Related news
Essex Bio-Technology Posts Sound 2023 Annual Financial Results: Revenue Up 29.5%, Profit Up 22.1%
2024-03-18
Essex Bio-Technology Posts Sound 2023 Interim Financial Results Revenue Up 37.1%, Profit Up 22%
2023-08-16
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
2023-07-26
Essex Bio-Technology Announces 2022 Annual Financial Results, Resilience & Relevance, Growth Ready
2023-03-08
Essex Bio-Technology to Present at the 5th China Bio-Pharm Partnering Forum (Bio-Pharm 2021)
2021-10-27
Application for Clinical Trial of Bevacizumab Has Been Approved for the Treatment of wAMD in Latvia
2021-04-20
Essex-Biotechnology Announces Bevacizumab for wAMD Has Received Clinical Trial Approval in Australia
2021-01-29
Essex Bio-Technology and Antikor Biopharma Forge Strategic Alliance in FDC for Cancer Treatment
2019-08-02
粵公網安備 44049102496184號